A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects with Refractory or Relapsed Lymphoid Malignancies
A study for subjects with refractory or relapsed lymphoid malignancies using study drug, AGS67E
Sponsor: Agensys, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAN8006
U.S. Govt. ID: NCT02175433
Contact: Michelle Malanga: 212-326-5720 / mm4629@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine a safe dose by testingthe investigational product, AGS67E at different dose levels. Secondly, to test what effects, good and/or bad, it has on subjects with refractory or relapsed non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) or hairy cell leukemia (HCL). We will also measure the levels of investigational product in subjects blood at different times.
This study is closed
Investigator
Ahmed Sawas, MD
Do You Qualify?
Do you have refractory or relapsed chronic lymphocytic leukemia, prolymphocytic leukemia, or hairy cell leukemia? Yes No
Are you currently taking any investigational drugs? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Michelle Malanga
mm4629@cumc.columbia.edu
212-326-5720
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE